Business Context and Reporting Period
This Form 8-K was filed by Aclaris Therapeutics, Inc. on April 13, 2022, reporting a current event under Item 7.01 (Regulation FD Disclosure). The company is incorporated in Delaware and trades on The Nasdaq Stock Market under the symbol ACRS.
Key Financial Metrics
The filing details a specific equity financing transaction rather than periodic financial performance metrics such as revenue or operating margins.
- Shares Sold: 4,838,709 shares of common stock.
- Weighted Average Price: $15.50 per share.
- Aggregate Gross Proceeds: $75.0 million.
- Transaction Mechanism: Sold pursuant to a sales agreement with SVB Securities LLC and Cantor Fitzgerald & Co. dated May 20, 2021.
The filing text does not provide clear values for revenue, profit, cash flow, debt, or liquidity positions outside of the proceeds from this specific transaction.
Material Changes
The primary material change reported is the increase in cash assets resulting from the $75.0 million gross proceeds from the common stock sale. No comparative period data is provided in this filing to assess changes in operational metrics.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific risk factors related to the transaction beyond the standard disclosure that the information in Item 7.01 is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the net proceeds after deducting underwriting discounts and commissions, as only gross proceeds ($75.0 million) are stated.
- Confirm the total number of shares outstanding post-transaction to assess dilution impact.
- Review the sales agreement dated May 20, 2021, for any remaining share availability or pricing constraints.
- Check subsequent filings for the intended use of the $75.0 million in proceeds.